全文获取类型
收费全文 | 8111篇 |
免费 | 550篇 |
国内免费 | 111篇 |
专业分类
耳鼻咽喉 | 13篇 |
儿科学 | 444篇 |
妇产科学 | 336篇 |
基础医学 | 564篇 |
口腔科学 | 31篇 |
临床医学 | 2211篇 |
内科学 | 1700篇 |
皮肤病学 | 15篇 |
神经病学 | 71篇 |
特种医学 | 118篇 |
外科学 | 1026篇 |
综合类 | 1046篇 |
预防医学 | 425篇 |
眼科学 | 7篇 |
药学 | 501篇 |
7篇 | |
中国医学 | 116篇 |
肿瘤学 | 141篇 |
出版年
2024年 | 8篇 |
2023年 | 224篇 |
2022年 | 131篇 |
2021年 | 407篇 |
2020年 | 302篇 |
2019年 | 288篇 |
2018年 | 271篇 |
2017年 | 346篇 |
2016年 | 295篇 |
2015年 | 300篇 |
2014年 | 522篇 |
2013年 | 529篇 |
2012年 | 425篇 |
2011年 | 497篇 |
2010年 | 384篇 |
2009年 | 362篇 |
2008年 | 338篇 |
2007年 | 406篇 |
2006年 | 293篇 |
2005年 | 289篇 |
2004年 | 250篇 |
2003年 | 218篇 |
2002年 | 198篇 |
2001年 | 197篇 |
2000年 | 184篇 |
1999年 | 179篇 |
1998年 | 119篇 |
1997年 | 95篇 |
1996年 | 81篇 |
1995年 | 81篇 |
1994年 | 86篇 |
1993年 | 51篇 |
1992年 | 48篇 |
1991年 | 51篇 |
1990年 | 23篇 |
1989年 | 27篇 |
1988年 | 23篇 |
1987年 | 13篇 |
1986年 | 18篇 |
1985年 | 29篇 |
1984年 | 26篇 |
1983年 | 21篇 |
1982年 | 29篇 |
1981年 | 23篇 |
1980年 | 18篇 |
1979年 | 9篇 |
1978年 | 7篇 |
1977年 | 10篇 |
1976年 | 14篇 |
1974年 | 7篇 |
排序方式: 共有8772条查询结果,搜索用时 250 毫秒
1.
2.
3.
Comprehensive evidence regarding the treatment of non-anaemic iron deficiency in patients undergoing valvular heart surgery is lacking. This study aimed to investigate the association between non-anaemic iron deficiency and postoperative outcomes in these patients. We retrospectively analysed 321 patients of which 180 (56%) had iron deficiency (defined as serum ferritin < 100 ng.ml-1 or < 300 ng.ml-1 with transferrin saturation < 20%). While the iron-deficient group had lower pre-operative haemoglobin levels than the non-iron deficient group (median (IQR [range]) 134 (127–141 [120–172]) g.l-1, 143 (133–150 [120–179]) g.l-1, p = 0.001), there was no between-group difference in allogeneic red blood cell transfusion. Median (IQR [range]) days alive and out of hospital at postoperative day 90 was 1 day shorter in the iron-deficient group (80 (77–82 [9–85]) days vs. 81 (79–83 [0–85]) days, p = 0.026). In multivariable analysis, only cardiopulmonary bypass duration (p = 0.032) and intra-operative allogeneic red blood cell transfusion (p = 0.011) were significantly associated with reduced days alive and out of hospital at postoperative day 90. Iron deficiency did not exert any adverse influence on secondary outcomes except length of hospital stay. Our findings indicate that non-anaemic iron deficiency alone is not associated with adverse effects in patients undergoing valvular heart surgery when it does not translate into an increased risk of allogeneic transfusion. 相似文献
4.
Aaron Pitzele Mohammad Rahimi Eric Armbrecht 《The journal of maternal-fetal & neonatal medicine》2015,28(15):1770-1773
Objective: To determine whether packed red blood cell (PRBC) transfusion affects post-prandial superior mesenteric artery blood flow velocities (SMA BFVs) in very-low birth weight (VLBW) neonates and if so, at what time point after transfusion restoration of previous SMA BFV patterns occurs.Design/Methods: VLBW pre-term neonates, older than 14 days and tolerating bolus enteral feedings administered every 3?h were enrolled in this prospective observational study. Pulsed Doppler ultrasound was used to measure pre- and post-prandial (at 45?min) time-averaged mean, peak and end diastolic velocities (TAMV, PSV, EDV) immediately before and after 15?ml/kg of PRBC transfusion was given over 3?h; patent ductus arteriosus (PDA) status was also evaluated. Subsequent pre- and post-prandial SMA BFVs were recorded 24 and 48?h after the transfusion.Results: Pre- and post-prandial measurements were obtained for 21 out of 25 enrolled infants. Post-prandial SMA BFVs were attenuated during the feedings immediately after transfusion; at 24 and 48?h after transfusion, changes in post-prandial SMA BFVs were similar to those measured prior to transfusion; the presence of the PDA did not affect results.Conclusions: PRBC transfusion blunted SMA BFV responses to feedings immediately after the transfusion with normalization observed 24?h post-transfusion. 相似文献
5.
Yesim Aydinok 《ISBT科学丛刊》2020,15(1):102-109
Lifetime red cell concentrate (RCC) transfusions still account for significant iron overload‐related morbidity and mortality despite chelation therapy in thalassaemia. The cumulative risk of transfusion‐transmitted infections is substantial for thalassaemia patients. Pathogen reduction technologies for RCC may imply a proactive approach against new/re‐emerging pathogens and may be an ultimate safeguard for transfusion safety in the developing countries. Red cell alloimmunization may become a significant clinical challenge in thalassaemia. The availability of high‐throughput molecular blood group antigen typing in the donors may allow perfect match transfusion, beyond ABO‐D and CEK antigen‐matched transfusions. Allogeneic stem cell transplantation (A‐SCT) is the only available curative therapy in thalassaemia, but carries a substantial risk of serious adverse events and mortality. Gene addition therapy for correction of the α‐globin chain imbalance overcomes the problems of donor availability and immunological complications of A‐SCT. Gene editing by either gene disruption or correction emerged as a potential alternative to gene addition therapy in beta‐thalassaemia. A new era of novel therapeutics targeting α/β imbalance, ineffective erythropoiesis or iron dysregulation is unfolding in thalassaemia management, and a number of those now have agents in preclinical and clinical development. Hydroxyurea (HU) may improve globin chain imbalance and be beneficial for reducing or omitting transfusion requirement. Ruxolitinib has allowed steady decrease in spleen volume that may serve for avoiding splenectomy in beta‐thalassaemia. Luspatercept may restore normal erythroid differentiation and improve anaemia. Hepcidin mimetics or TMPRSS6 inhibitors may modulate ineffective erythropoiesis by iron restriction and improve anaemia and organ iron loading. 相似文献
6.
Bernard Natukunda Grace Ndeezi Lay See Er Francis Bajunirwe Gayle Teramura Meghan Delaney 《ISBT科学丛刊》2019,14(4):366-373
7.
8.
《Burns : journal of the International Society for Burn Injuries》2021,47(5):1038-1044
IntroductionAlthough blood transfusion is common in burns, data are lacking in appropriate transfusion thresholds. It has been reported that a restrictive blood transfusion policy decreases blood utilization and improves outcomes in critically ill adults, but the impact of a restrictive blood transfusion policy in burn patients is unclear. We decided to investigate the outcome of decreasing the blood transfusion threshold.Material and methodsEighty patients with TBSA > 20% who met our inclusion criteria were included. They were randomly divided into control and intervention groups. The intervention group received packed cells only when Hemoglobin declined to less than 8 g/dL at routine laboratory evaluations. While the control group received packed-cell when hemoglobin was declined to less than 10 g/dl. The total number of the received packed cell before, during and after any surgical procedure was recorded. The outcome was measured by the evaluation of the infection rate and other complications.ResultThe mean hemoglobin level before transfusion was 7.7 ± 0.4 g/dL in the restrictive group and 8.8 ± 0.7 g/dL in the liberal group. The mean number of RBC unit transfusion per patient in the restrictive group was significantly lower than the traditional group (3.28 ± 2.2 units vs. 5.9 ± 3.7 units) (p-value = 0.006). The total number of RBC transfused units varied significantly between the two groups (p-value = 0.014). The number of transfused RBC units outside the operation room showed a significant difference between groups (restrictive: 2.8 ± 1.4 units vs. liberal: 4.4 ± 2.6 units) (p = 0.004). We did not find any significant difference in mortality rate or other outcome measures between groups.ConclusionApplying the restrictive transfusion strategy in thermal burn patients who are highly prone to all kinds of infection, does not adversely impact the patient outcome, and results in significant cost savings to the institution and lower rate of infection. We conclude that the restrictive transfusion practice during burn excision and grafting is well tolerated and effective in reducing the number of transfusions without increasing complications.Clinical Trial Registration ReferenceIRCT20190209042660N1. 相似文献
9.
10.